ARTICLE | Clinical News
Nexvax2: Ph Ib data
March 17, 2017 4:25 PM UTC
A double-blind, placebo-controlled, Australian and New Zealand Phase Ib trial in 38 celiac disease patients on a gluten-free diet showed that twice-weekly intradermal Nexvax2 for up to 60 days was wel...
BCIQ Company Profiles